The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Mikhaĭlova M.A.

Kafedra glaznykh bolezneĭ GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova"

Sizova M.V.

FGBU "NII glaznykh bolezneĭ" RAMN

Shelankova A.V.

FGBU "NII glaznykh bolezneĭ" RAMN

Pathogenesis of retinal vein occlusions

Authors:

Mikhaĭlova M.A., Sizova M.V., Shelankova A.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2014;130(2): 88‑92

Read: 1380 times


To cite this article:

Mikhaĭlova MA, Sizova MV, Shelankova AV. Pathogenesis of retinal vein occlusions. Russian Annals of Ophthalmology. 2014;130(2):88‑92. (In Russ.)

Recommended articles:
Features of arte­rial blood flow velo­city characteristics in endo­thelial dysfunction. Russian Journal of Preventive Medi­cine. 2024;(12):100-106
The level of hypo­xia-induced factor-1a and asso­ciated mole­cules in preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):5-10
Correlation between endo­thelial dysfunction and sensorineural hearing loss. Russian Bulletin of Otorhinolaryngology. 2025;(3):13-18
Diagnostic stra­tegies for post-COVID syndrome. Russian Journal of Preventive Medi­cine. 2025;(6):126-130

References:

  1. Yau J.W., Lee P., Wong T.Y., Best J., Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern. Med. J 2008; 38 (12): 904-910.
  2. Cugati S., Wang J.J., Rochtchina E., Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch. Ophthalmol 2006; 124 (5): 726-732.
  3. Klein R., Moss S.E., Meuer S.M., Klein B.E. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch. Ophthalmol 2008; 126 (4): 513-518.
  4. Rogers S., McIntosh R.L., Cheung N., Lim L., Wang J.J., Mitchell P., Kowalski J.W., Nguyen H., Wong T.Y. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. International Eye Disease Consortium. Ophthalmology 2010; 117 (2): 313-319.
  5. Klein R., Klein B.E., Lee K.E., Cruickshanks K.J., Gangnon R.E. Changes in visual acuity in a population over a 15 year period: the Beaver Dam Eye Study. Am. J. Ophthalmol 2006; 142 (4): 539-549.
  6. Kiseleva T.N., Koshevaya O.P., Budzinskaya M.V., Shchegoleva I.V. Blood flow in the vessels of the eye in central retinal vein occlusion. Kataraktal'naya i refraktsionnaya khirurgiya. 2006; 6 (3): 52-56. (In Russ.)
  7. Libman E.S., Shakhova E.V. State and dynamics of blindness and disability due to eye pathology in Russia. In: Materialy VII s"ezda oftal'mologov Rossii Proc. of The 7th Congress of Russ. ophthalmologists : Abstracts, p. 2. Moscow; 2000; 209-214. (In Russ.)
  8. Martin S.C., Butcher A., Martin N., Farmer J., Dobson P.M., Bartlett W.A., Jones A.F. Cardiovascular risk assessment in patients with retinal vein occlusion. Br. J. Ophthalmol 2002; 86 (7): 774-776.
  9. Tsaloumas M.D., Kirwan J., Vinall H., O'Leary M.B., Prior P., Kritzinger E.E., Dodson P.M. Nine-year follow-up study of morbidity and mortality in retinal vein occlusion. Eye 2000; 14: 821-827.
  10. Cugati S., Wang J.J., Knudtson M.D., Rochtchina E., Klein R., Klein B.E., Wong T.Y., Mitchell P. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007; 114 (3): 520-524.
  11. Tul'tseva S.N., Astakhov Yu.S. Okklyuzii ven setchatki. Etiologiya, patogenez, klinika, diagnostika, lechenie Retinal veins occlusion. Etiology, pathogenesis, clinical features, diagnosis, treatment . St. Petersburg: "N-L" Publ.; 2010.
  12. Avetisov S.E., Smirnova T.V., Kozlovskaya N.L., Kiseleva T.N., Eliseeva E.G., Budzinskaya M.V., Murakhovskaya T.V. Vaso-occlusive retinopathy in patient with primary antiphospholipid syndrome. Vestnik oftal'mologii. 2007; 123 (3): 46-48. (In Russ.)
  13. Katsnel'son L.A Farafonova T.I., Bunin A.Ya. Sosudistye zabolevaniya glaza Vascular diseases of the eye . Moscow: Meditsina Publ.; 1990.
  14. David R., Zangwill L., Badarna M., Yassur Y. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 1988; 197 (2): 69-74.
  15. Tankovskiy V.E. Trombozy ven setchatki Thromboses of retinal veins . Moscow: Voenizdat, 4th branch Publ.; 2000.
  16. Mikhaylova M.A., Plyukhova A.A., Balatskaya N.V., Budzinskaya M.V. Features of the development of occlusive vascular lesions of the retina and optic nerve on a background of cardiovascular diseases. Prakticheskaya meditsina. 2012; 2 (59): 71-74. (In Russ.)
  17. Fujino T., Curtin V.T., Norton E.W. Experimental central retinal vein occlusion: a comparison of intraocular and extraocular occlusion. Trans. Am. Ophthalmol. Soc 1968; 66: 318-378.
  18. Kohner E.M., Dollery C.T., Shakib M., Henkind P., Paterson J.W., De Oliveira L.N., Bulpitt C.J. Experimental retinal branch vein occlusion. Am. J. Ophthalmol 1970; 69 (5): 778-825.
  19. Duker J.S., Brown G.C. Anterior location of the crossing artery in branch retinal vein obstruction. Arch. Ophthalmol. 1989; 107 (7): 998-1000.
  20. Zhao J., Sastry S.M., Sperduto R.D., Chew E.Y., Remaley N.A. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology 1993; 100 (3): 423-428.
  21. Akman A., Kadayifçilar S., Aydin P. Effects of hypertension on the retinal vein width at the retinal arteriovenous crossings. Eur. J. Ophthalmol 1998; 8 (2): 71-75.
  22. Jefferies P., Clemett R., Day T. An anatomical study of retinal arteriovenous crossings and their role in the pathogenesis of retinal branch vein occlusions. Aust. N. Z. J. Ophthalmol 1993; 21 (4): 213-217.
  23. Plyukhova A.A., Balatskaya N.V., Budzinskaya M.V. Changes in the organ of vision in systemic atherosclerosis. Vestnik oftal'mologii. 2013; 1: 71-74. (In Russ.)
  24. Budzinskaya M.V., Fedorov A.A., Plyukhova A.A., Voevodina T.M., Balatskaya N.V. Morphological manifestations of systemic atherosclerosis of fundus structures (experimental research). Vestnik oftal'mologii. 2013; 2: 3-7. (In Russ.)
  25. Staurenghi G., Lonati C., Aschero M., Orzalesi N. Arteriovenous crossing as a risk factor in branch retinal vein occlusion. Am. J. Ophthalmol 1994; 117 (2): 211-213.
  26. Baglivo E., Dosso A., Pournaras C. Thrombus and branch retinal vein occlusion. Graefes. Arch. Clin. Exp. Ophthalmol 1997; 235 (1): 10-13.
  27. Messerli J., Flammer J. Central vein thrombosis in younger patients. Klin. Monbl. Augenheilkd 1996; 208 (5): 303-305.
  28. Lysenko V.S. Gemorragicheskiy sindrom pri sosudistykh zabolevaniyakh setchatki (patogenez, lechenie, profilaktika): Avtoref. dis. d-ra med. nauk Hemorrhagic syndrome in vascular diseases of the retina (pathogenesis, treatment, prevention). Dr. Diss. (Med. Sci.) . Moscow; 2003.
  29. Tul'tseva S.N.  Endothelial regulators of fibrinolysis in patients with retinal veins thrombosis. Oftal'mologicheskie vedomosti. 2009; 2 (1): 4-11. (In Russ.)
  30. Petrishchev N.N. Disfunktsiya endoteliya. Prichiny, mekhanizmy, farmakologicheskaya korrektsiya Endothelial dysfunction. Causes, mechanisms, pharmacological correction . St. Petersburg: St. Petersburg State Medical University Publ.; 2003.
  31. Rehak M., Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J. Thromb. Haemost 2010; 8 (9): 1886-1894.
  32. Haufschild T., Prünte C., Messerli J., Flammer J. Increased endothelin-1 plasma level in young adults with retinal vascular occlusive diseases. Klin. Monbl. Augenheilkd 2004; 221 (5): 357-359.
  33. Güven D., Sayinalp N., Kalayci D., Dündar S., Hasiripi H. Risk factor in central vein occlusion and activated protein C resistance. Eur. J. Ophthalmol 1999; 9 (1): 43-48.
  34. Stojakovic T., Scharnagl H., März W., Winkelmann B.R., Boehm B.O., Schmut O. Low density lipoprotein triglycerides and lipoprotein a are risk for retinal vein occlusion. Clin. Chim. Acta 2007; 382 (1-2): 77-81.
  35. Sodi A., Giambene B., Marcucci R., Sofi F., Fedi S., Abbate R., Prisco D., Menchini U. Atherosclerotic and thrombophilic risk factors in patients with ischemic central retinal vein occlusion. Retina 2011; 31 (4): 724-729.
  36. Wollensak G., Schaefer H.E., Ihling C. An immunohistochemical study of endothelin-1 in the human eye. Curr. Eye Res 1998; 17 (5): 541-545.
  37. Narayan S., Brun A.M., Yorio T. Endothelin-1 distribution and basolateral secretion in the retinal pigment epithelium. Exp. Eye Res 2004; 79 (1): 11-19.
  38. Takei K., Sato T., Nonoyama T., Miyauchi T., Goto K., Hommura S. A new model of transient complete obstruction of retinal vessels induced by endothelin-1 injection into the posterior vitreous body in rabbits. Graefes Arch. Clin. Exp. Ophthalmol 1993; 231: 476-481.
  39. Takagi C., Bursell S.E., Lin Y.W., Takagi H., Duh E., Jiang Z., Clermont A.C., King G.L. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest. Ophthalmol. Vis. Sci 1996; 37: 2504-2518.
  40. Iannaccone A., Letizia C., Pazzaglia S., Vingolo E.M., Clemente G., Pannarale M.R. Plasma endothelin-1 concentrations in patients with retinal vein occlusions. Br. J. Ophthalmol 1998; 82 (5): 498-503.
  41. Rodeheffer R.J., Lerman A., Heublein D.M., Burnett J.C. Jr. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin. Proc. 1992; 67 (8): 719-24.
  42. Fraenkl S.A., Mozaffarieh M., Flammer J. Retinal vein occlusions: The potential impact of a dysregulation of the retinal veins. EPMA J 2010; 1 (2): 253-261.
  43. Haufschild T., Prünte C., Messerli J., Flammer J. Increased endothelin-1 plasma level in young adults with retinal vascular occlusive diseases. Klin. Monbl. Augenheilkd 2004; 221 (5): 357-359.
  44. Stangos A.N., Petropoulos I.K., Pournaras J.A., Mendrinos E., Pournaras C.J. The vasodilatory effect of juxta-arteriolar microinjection of endothelin A receptor inhibitor in healthy and acute branch retinal vein occlusion minipig retinas. Invest. Ophthalmol. Vis. Sci 2010; 51 (4): 2185-2190.
  45. Yorio T., Krishnamoorthy R., Prasanna G. Endothelin: is it a contributor to glaucoma pathophysiology? J. Glaucoma 2002; 11 (3): 259-270.
  46. Egorova T.E. Antioxidants in the treatment and prevention of the dry form of age-related macular degeneration. literature Review. Russkiy meditsinskiy zhurnal. 2010; 2: 69-72. (In Russ.)
  47. Men'shchikova E.B., Lankin V.Z., Zenkov N.K. Okislitel'nyy stress. Prooksidanty i antioksidanty Oxidative stress. Prooxidants and antioxidants . Moscow: Slovo Publ.; 2006.
  48. Mullan B., Duffy M., McAuley. Antioxidants for the treatment of endothelial dysfunction in critical illness. In: Yearbook of intensive care and emergency medicine, 2007. Vincent J.-L. (ed.). Berlin: Springer 2007; 173-187.
  49. MacCallum N.S., Quinlan G.J., Evans T.W. The role of neutrophil-derived myeloperoxidase in organ dysfunction and sepsis. In: Yearbook of intensive care and emergency medicine, 2007. Vincent J.-L. (ed.). Berlin: Springer 2007; 173-187.
  50. Rakugi H., Tabuchi Y., Nakamura M., Nagano M., Higashimori K., Mikami H., Ogihara T., Suzuki N. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem. Biopthys. Res. Commun 1990; 169: 973-977.
  51. Murphy M.H., Packer M.A., Scarlett J.L. Martin S.W. Peroxynitrite: a biologically significant oxidant. Gen. Pharmacol 1998; 31: 179-186.
  52. Budzinskaya M.V., Mikhaylova M.A., Balatskaya N.V. Prerequisites for application of the histochrom drug with a disbalance of redox system caused by the retinal venous occlusions Effektivnaya farmakoterapiya. 2013; 1: 36-40. (In Russ.)
  53. Plyukhova A.A., Mikhaylova M.A., Budzinskaya M.V., Balatskaya N.V., Soboleva G.N., Shchegoleva I.V. Morphometric characteristics of fundus structures and antioxidant status in patients with systemic cardiovascular diseases . Oftal'mologiya. Vostochnaya Evropa. 2012; 4 (15): 37-43. (In Russ.)
  54. Scholl S., Augustin A., Loewenstein A., Rizzo S., Kupperman B. General pathophysiology of macular edema. Eur. J. Ophthalmol 2011; (21, Suppl. 6): 10-19.
  55. Yoshimura T., Sonoda K.H., Sugahara M., Mochizuki Y., Enaida H., Oshima Y., Ueno A., Hata Y., Yoshida H., Ishibashi T. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009; 4 (12).
  56. Scholl S., Kirchhof J., Augustin A.J. Pathophysiology of macular edema. Ophthalmologica 2010; 224 (Suppl. 1): 8-15.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.